GlassScriptPhysician profile
Mitra Delshad
NPI 1659735637
$8,733.02
in general payments reported to CMS, 2019-2025
39 companies · $2,167 in 2025
The $2,167 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $401 · 2022: $655 · 2023: $2,716 · 2024: $2,793 · 2025: $2,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,676.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,215.68 | 2022-2025 | |
| Novo Nordisk INC | $1,189.77 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Daiichi Sankyo INC. | $644.27 | 2023-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $463.57 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $452.25 | 2023-2025 | Breztri, Farxiga, Fasenra |
| Axsome Therapeutics, INC. | $424.86 | 2024-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $418.89 | 2022-2023 | Xifaxan |
| Amgen INC. | $303.67 | 2023-2025 | Repatha, Otezla, Repatha |
| Vanda Pharmaceuticals INC. | $294.39 | 2024-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $196.67 | 2023-2025 | Jardiance, Emgality, Zepbound |
| Kyowa Kirin, INC. | $165.93 | 2023-2024 | Crysvita |
| Glaxosmithkline, LLC. | $155.67 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Medtronic, INC. | $139.20 | 2023 | Venaseal |
| Exact Sciences Corporation | $135.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.05 | 2024-2025 | Caplyta |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $129.29 | 2022-2023 | Pifeltro, Dificid, Delstrigo |
| Stryker Corporation | $124.80 | 2024 | Infinity Adaptis |
| Pfizer INC. | $111.01 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $108.57 | 2023 | Quviviq |
| Genzyme Corporation | $103.56 | 2024 | |
| Indivior INC. | $100.69 | 2023-2025 | Sublocade |
| Abbott Laboratories | $93.50 | 2025 | Jot Dx |
| Theratechnologies INC. | $80.59 | 2023 | Egrifta, Trogarzo |
| Janssen Pharmaceuticals, INC | $67.96 | 2023-2024 | Invega Sustenna, Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $67.81 | 2022 | |
| Astellas Pharma US INC | $59.06 | 2023-2024 | Veozah |
| Alk-Abello, INC | $49.87 | 2023-2025 | Grastek, Odactra |
| Dexcom, INC. | $46.56 | 2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $40.04 | 2025 | Voquezna |
| Sanofi Pasteur INC. | $33.47 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $32.54 | 2025 | Jornay Pm |
| Edwards Lifesciences Corporation | $28.03 | 2023 | Sapien 3 Ultra Resilia |
| Hologic Sales and Service, LLC | $22.94 | 2024 | Aptima |
| Vertex Pharmaceuticals Incorporated | $22.47 | 2025 | |
| Janssen Biotech, INC. | $18.83 | 2023 | Tremfya |
| Gilead Sciences, INC. | $17.54 | 2025 | |
| Viiv Healthcare Company | $14.95 | 2023 | Dovato |
| Neurocrine Biosciences, INC. | $13.63 | 2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $13.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitra Delshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.